Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2003;327 (20 September), doi:10.1136/bmj.327.7416.0-g
| The first 150 words of the full text of this article appear below. |
The United States is hugely important for drug companies. The pharmaceutical market is worth more than $150bn, and annual spending has been rising by almost 20% a year (p 642). Prices are not regulated in the way they are in many other countries, and companies are allowed to advertise directly to consumersso boosting consumption. But now the cost of drugs has become an important political issue, and a bill has been introduced into Congress that would require government agencies to gather evidence "comparing effectiveness [and] cost effectiveness" of the most commonly prescribed drugs "relative to other drugs or treatments for the same disease."
The bill aims to reduce costs, but it could also improve quality. The proposal is to conduct many more head to head trials of common treatmentstrials like the ALLHAT (antihypertensive and lipid lowering to prevent heart attack trial), which showed that diuretics are just as
Richard Smith, editor
(rsmith@bmj.com)
Read all Rapid Responses